8-K: Orgenesis Inc. Announces 1-for-10 Reverse Stock Split to Regain Nasdaq Compliance

Orgenesis Inc. has announced a 1-for-10 reverse stock split to increase its share price and regain compliance with Nasdaq's minimum bid price requirement.

Summary

• Orgenesis Inc. has approved a 1-for-10 reverse stock split of its common stock.
• The reverse stock split is scheduled to take effect at 5:00 pm New York time on September 24, 2024.
• The company's stock will begin trading on a split-adjusted basis on September 25, 2024, under the existing ticker symbol ORGS.
• The primary reason for the reverse stock split is to raise the per share price above $1.00 to comply with Nasdaq listing rules.
• The company needs to maintain a share price of $1.00 or higher for at least 10 consecutive trading days to regain full compliance.
• The reverse stock split will reduce the number of outstanding shares from 47,707,849 to approximately 4,770,785.
• The total authorized shares will be reduced from 145,833,334 to 14,583,333.
• Fractional shares resulting from the split will be rounded down, and shareholders will receive a cash payment based on the closing price on September 24, 2024.
• The CUSIP number for the common stock will change to 68619K303.
• All outstanding options, warrants, and convertible debt will be adjusted proportionally to reflect the reverse stock split.

Sentiment

Score: 4

Explanation: The document indicates a necessary but potentially concerning action (reverse stock split) to maintain listing compliance. While the company is taking steps to address the issue, the underlying reason for the split suggests some financial challenges. The forward-looking statements also highlight significant risks.

Positives

• The reverse stock split is a necessary step to regain compliance with Nasdaq listing rules, which could improve investor confidence.
• The company will provide cash payments for fractional shares, ensuring fair treatment for all shareholders.
• The reverse stock split will not alter the stockholders percentage ownership interest in the Company, except for minor adjustments due to fractional shares.

Negatives

• The reverse stock split is a sign that the company's share price has fallen below the required minimum, which may be concerning to investors.
• The reduction in the number of outstanding shares could potentially increase volatility in the stock price.

Risks

• The company may not be successful in maintaining the listing of its common stock on Nasdaq.
• The reverse stock split may not have the desired effect of increasing the share price and maintaining compliance.
• The company's ability to secure additional capital is a risk factor.
• The company's reliance on its point-of-care cell therapy platform is a risk.
• The company's ability to achieve and maintain overall profitability is a risk.
• The company's research and development programs are based on novel technologies, which carries inherent risks.
• The company's ability to control key elements relating to the development and commercialization of therapeutic product candidates with third parties is a risk.
• The timing of completion of clinical trials and studies is a risk.
• The availability of additional data and outcomes of clinical trials of the company's product candidates are risks.
• The potential uses and benefits of the company's product candidates are risks.
• The sufficiency of working capital to realize the company's business plans and its ability to raise additional capital are risks.
• The development of the company's POCare strategy is a risk.
• The company's trans differentiation technology as therapeutic treatment for diabetes is a risk.
• The technology behind the company's in-licensed ATMPs not functioning as expected is a risk.
• The company's ability to further its CGT development projects, either directly or through its JV partner agreements, and to fulfill its obligations under such agreements is a risk.
• The company's license agreements with other institutions are a risk.
• The company's ability to retain key employees is a risk.
• The company's competitors developing better or cheaper alternatives to its products is a risk.
• Risks relating to legal proceedings against the company are a risk.

Future Outlook

The company aims to regain compliance with Nasdaq's minimum bid price requirement through the reverse stock split, but there is no guarantee of success. The company's future performance is subject to various risks and uncertainties.

Management Comments

• The Board of Directors approved the 1-for-10 reverse stock split.
• The company is effectuating the Reverse Stock Split to raise the per share bid price of the Company's Common Stock above $1.00 per share and bring the Company back into compliance with Nasdaq Listing Rule 5550(a)(2).

Industry Context

Reverse stock splits are a common strategy for companies facing delisting from major exchanges due to low share prices. This action is not unique to Orgenesis and is often seen in the biotech sector, where companies may experience volatility in their stock prices due to the nature of their research and development activities.

Comparison to Industry Standards

• Many biotech companies facing similar listing compliance issues have implemented reverse stock splits.
• For example, companies like Agenus Inc. and Cellectar Biosciences have also recently undergone reverse stock splits to maintain their Nasdaq listings.
• The 1-for-10 ratio is a common ratio for reverse stock splits, although the specific ratio can vary depending on the company's situation.
• The goal of these actions is to increase the share price to meet the minimum bid price requirement of $1.00 per share, which is a standard requirement for Nasdaq listing.

Stakeholder Impact

• Shareholders will experience a reduction in the number of shares they own, but their proportional ownership will remain virtually unchanged.
• Shareholders holding fractional shares will receive a cash payment.
• The reverse stock split is intended to benefit shareholders by maintaining the company's listing on Nasdaq.
• Employees may be impacted by the company's financial performance and the need to maintain listing compliance.
• Customers and suppliers may be indirectly affected by the company's financial stability and ability to operate.

Next Steps

• The company will begin trading on a split-adjusted basis on September 25, 2024.
• The company needs to maintain a share price of $1.00 or higher for at least 10 consecutive trading days to regain full compliance with Nasdaq listing rules.
• Stockholders holding paper certificates must send them to Securities Transfer Corporation to receive new shares in book entry form.

Key Dates

Keywords

reverse stock split, Nasdaq compliance, share price, common stock, ORGS, stock split, CUSIP number, biotech, cell and gene therapy